Beyond Air, Inc. (XAIR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beyond Air, Inc., a Delaware corporation and emerging growth company, on November 12, 2020, regarding events occurring on November 11, 2020. The Company is headquartered in Garden City, NY, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "XAIR".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory milestone rather than financial performance data.
Material Changes
The primary material event reported is the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Company's LungFit PH device. This device is intended to treat persistent pulmonary hypertension of the newborn.
Guidance, Outlook, and Risks
Management commentary indicates that FDA guidelines allow for a 180-day review period for the submitted PMA application. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard regulatory review process associated with the PMA submission.
Investor Verification Checklist
- Verify the status of the LungFit PH PMA application with the FDA.
- Confirm the expected timeline for the 180-day FDA review period.
- Review the attached Press Release (Exhibit 99.1) for detailed clinical data supporting the submission.
- Monitor subsequent filings for any FDA responses or requests for additional information.